펜실베이니아의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 23개가 펜실베이니아 내 여러 지역에서 참여자를 모집하고 있습니다.
펜실베이니아의 도시
공식 연구 텍스트(영어)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- AHN West Penn Hospital, Pittsburgh
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06152575Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Perelman Center for Advanced Medicine, Philadelphia
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07555938A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Penn State Milton S Hershey Medical Ctr, Hershey
- Allegheny Health Network, Pittsburgh
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07258511AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Philadelphia
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06106945A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- AHN West Penn Hospital, Pittsburgh
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06615479Collection of Tissue Samples for Cancer Research
- University of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중관찰 연구
2 Months · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT00900198A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- University of Pennsylvania, Philadelphia
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Philadelphia
- Research Site, Philadelphia
피험자 모집 중3상
18세 ~ 130세 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07735637Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Penn State Hershey Medical Center, Hershey
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT07648264Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT06297226Limited-duration Teclistamab
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Honickman Center, Philadelphia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT05932680A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Penn Medicine, Philadelphia
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lehigh Valley Hospital - Cedar Crest, Allentown
- Lehigh Valley Hospital- Muhlenberg, Bethlehem
- Pocono Medical Center, East Stroudsburg
- 외 2개
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Pocono Medical Center, East Stroudsburg
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT04566328Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 24. 업데이트됨 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- 외 5개
피험자 모집 중3상
전 연령 · 모든 성별 · 2026. 6. 10. 업데이트됨 · NCT05561387Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 6. 5. 업데이트됨 · NCT03858205A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- Allegheny Health Network, Pittsburgh
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555Mozobil for Autologous Hematopoietic Stem Cell Transplantation
- Thomas Jefferson University Hospital, Philadelphia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 11. 28. 업데이트됨 · NCT07188090Two Step Haplo With Radiation Conditioning
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 10. 30. 업데이트됨 · NCT05031897ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.